Bioceros has a high-yield cell line development platform as well as comprehensive process development and analytical capabilities. It will be integrated with Polpharma Group’s Biologics Unit to support the development of biosimilars and other biotechnological drugs for global markets.
“We are very happy to add an industry-leading cell line technology platform, great process development capabilities and a team of senior industry experts to our existing development set-up in Gdansk,” said Markus Sieger, CEO of Polpharma Group. “With Bioceros we will be fully integrated in our biotechnological development capabilities, which is a key success factor for our strategic direction, the development of biosimilars. We look forward to applying this new technology to bring more cost-effective treatment alternatives for serious diseases to patients worldwide.” With this acquisition Polpharma Group will be able to master all steps of the biotech value chain from cell line via process and product development to GMP manufacturing. This is not only highly complementary to the state-of-the-art facilities of Polpharma Biologics in Gdansk, but also accelerates its entry into the CDMO space.
